 | | Vol. 16.10 – 14 March, 2024 |
| |
|
|
| Through a genome-wide CRISPR screen, investigators identified protein arginine methyltransferase 5 (PRMT5) as a molecular vulnerability in ER+/RB1-knockout breast cancer cells.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors reported that coactivator-associated arginine methyltransferase 1 (CARM1) promoted proliferation, epithelial–mesenchymal transition, and stemness in TNBC.
[Protein & Cell] |
|
|
|
| Investigators showed that metastatic TNBC tumors harbored more unsaturated phospholipids, especially long-chain polyunsaturated fatty acids, at the sn-2 position of phosphatidylcholine and phosphatidylethanolamine compared to primary tumors.
[Cancer Research] |
|
|
|
| Scientists sought to classify each breast cancer cell line as poorly or highly metastatic by characterizing tumor growth and metastasis in a murine model of six commonly used human TNBC xenografts.
[Breast Cancer Research] |
|
|
|
| Using TNBC systems, the authors discovered the aryl hydrocarbon receptor suppressed type I interferon expression via inhibition of stimulator of interferon genes (STING), a key mediator of interferon production.
[Scientific Reports] |
|
|
|
| Researchers investigated the inhibitory effect of microRNA-561-3p on ZEB1, HIF1A, and MYC expression as oncogenes that have the most impact on programmed death ligand 1 (PD-L1) overexpression and cellular processes such as proliferation, apoptosis, and cell cycle in breast cancer cell lines.
[Scientific Reports] |
|
|
|
|
| The authors address clinical and preclinical approaches to treating breast cancer dormancy, how precisely controlled artificial environments reveal key interactions that regulate breast cancer dormancy, and how future generations of biomaterials could answer further questions about breast cancer dormancy.
[Science Advances] |
|
|
|
| Scientists discuss the unique regulatory mechanisms of cuproptosis, ferroptosis and pyroptosis in breast cancer, and the mechanisms through which they are affected by conventional cancer drugs.
[International Journal of Oncology] |
|
|
|
|
| Dr. Angelica Lang’s research project received $348,076 over four years from the Canadian Institutes of Health Research Project Grant program. Lang’s research explores relationships between types of surgeries and subsequent movement pattern alterations, as well as their implications for post-surgery rehabilitation.
[University of Saskatchewan College of Medicine] |
|
|
|
|
| April 22 – 25, 2024
Baltimore, Maryland, United States |
|
|
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | Princess Margaret Cancer Centre – Toronto, Ontario, Canada |
|
|
|
| | Montreal Clinical Research Institute РMontr̩al, Qu̩bec, Canada |
|
|
|
| | Augusta University – Augusta, Georgia, United States |
|
|
|
| | UC Davis – Davis, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
